hotspot -WSS

hotspot

author：leisure time 2025-09-05 09:16:29 - browse：81287

Adam's take main illustration — Molly Ferguson/STAT

For two days starting on Sunday, Moonlake Immunotherapeutics happily crunched numbers and shared results from a mid-stage clinical trial that depicted its experimental antibody in the most flattering terms possible.

The drug, called sonelokimab, was “changing the game” for the treatment of a debilitating skin condition called hidradenitis suppurativa, or HS, said Moonlake CEO Jorge Santos da Silva, on a call for investors and analysts. The drug’s benefit for patients placed it “at the top of the heap,” he added.

For other, equally important data from the same study that did not fit Moonlake’s home-run narrative, the company took a DIY approach. Curious about how sonelokimab performed against a treatment that’s already approved for HS? Pull out a calculator and do the math yourself. How badly did a higher dose of the drug underperform a lower dose? Take a guess.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： A clever new way to fix Medicaid and graduate medical education

hotspot

knowledge

WSS

White House calls on federal agencies to crack down on AI abuses

The new shift in health care is toward less care

In diabetes hearing, Sanders takes on a new foe: food makers

Medicare solvency divides Republicans at the presidential debate

Diversify hospital leadership teams to protect BIPOC patient health

FDA approves Recor Medical high blood pressure device

entertainment

hotspot

knowledge

Bright Health sells Medicare Advantage business to Molina

Ambulance rides for just $100? Advisers want major billing fixes

BioMarin wins approval for gene therapy to treat hemophilia A

Pregnancy discrimination could be enabled by AI

How one medical school became remarkably diverse

Free speech concerns arise in wake of journal editor Eisen's firing

Supreme Court strikes down use of affirmative action

Sanofi CEO defends move to abandon profit guidance, boost research

Psychedelics group wrestles with new pharma identity

Why sickle cell disease is getting the first CRISPR treatment

focus

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Teach medical students about patients with intellectual disabilities

FDA approves world's first CRISPR

After sickle

STAT Executive Editor Rick Berke on STAT's 8th birthday

Diversify hospital leadership teams to protect BIPOC patient health

hotspot

Wikipedia

knowledge

focus